Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetic Equivalence of QL2107 vs Keytruda in Resected Non-Small Cell Lung Cancer
NCT07162883Phase 3Active, not recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Nov 2025
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 13
01
Overview
A Phase 3 trial of QL2107 in non-small cell lung cancer (NSCLC), sponsored by Qilu Pharmaceutical. Started Nov 2025; status: active, not recruiting.
02
Drugs
QL2107
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07162883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07162883.